TNR News Network
Shimla: In a significant boost to India’s public health programme, the Central Research Institute (CRI) at Kasauli in Solan district of Himachal Pradesh has developed a single-dose vaccine that offers protection against both tetanus and diphtheria.
The vaccine has successfully completed its clinical trials and has been found effective in generating antibodies against both diseases. It is expected to be rolled out in government hospitals in the coming days, following its formal launch by Union Health Minister JP Nadda.
From two injections to one
Until now, tetanus and diphtheria were administered through separate vaccines, often causing discomfort and logistical challenges, especially for children. Scientists at CRI-Kasauli began research on combining the two vaccines into a single injection in 2019.
Despite disruptions during the Covid-19 pandemic, the research team continued its work and has now achieved a breakthrough by developing a combined formulation that is safe and effective.
According to officials, the single-dose vaccine will simplify immunisation schedules, reduce the burden on healthcare systems and improve vaccine compliance among beneficiaries.
Clinical trials show promising results
The vaccine has cleared all required clinical trial stages, during which it demonstrated strong antibody response against both tetanus and diphtheria.
“The trials confirmed that the combined vaccine is effective and meets safety standards,” said a scientist at the CRI-Kasauli. He added that the vaccine will soon be formally introduced and made available through the public healthcare network.
Health experts believe the new vaccine will play an important role in preventing tetanus infections caused by cuts or wounds, as well as diphtheria, a contagious disease that primarily affects children but can occur in all age groups.
CRI-Kasauli’s legacy in vaccine research
Established on May 3, 1905, the Central Research Institute, Kasauli, is among India’s oldest and most prestigious vaccine research centres. The institute has been at the forefront of vaccine and serum production for over a century and has contributed significantly to public health in India and abroad.
The CRI also played a crucial role in treating injured soldiers during World War II and was the country’s first central government institution to manufacture the DPT vaccine.
With the development of the combined tetanus-diphtheria vaccine, CRI-Kasauli has once again reinforced its position as a key pillar of India’s immunisation and disease-prevention efforts.
